Filing Flows › Cytosorbents (CTSO) › Q1 2026 › vs Q1 2025
Cytosorbents (CTSO) Q1 2026 vs Q1 2025 (year over year)
Cytosorbents's revenue rose $137K (+2%) from $8.7M in Q1 2025 to $8.9M in Q1 2026.
Cytosorbents, Q1 2026: revenue $8.9M (+2% year over year), operating margin -34.3%, net loss $5.1M, operating cash flow −$1.2M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $8.9M | $8.7M | $137K | +2% |
| Net loss | $5.1M | $1.5M | $3.6M | +247% |
| Costs & expenses | $14.0M | $12.6M | $1.4M | +11% |
| Operating costs | $11.9M | $12.6M | −$707K | -6% |
| Interest & other, net | $2.1M | −$2.4M | $4.5M | — |
| Cost of revenue | $2.7M | $2.5M | $214K | +8% |
| Research & development | $1.0M | $1.7M | −$638K | -38% |
| SG&A | $8.1M | $8.4M | −$283K | -3% |
| Operating cash sources | $5.1M | $1.5M | $3.6M | +247% |
| Depreciation & amortization | $350K | $369K | −$19K | -5% |
| Share-based compensation | $544K | $818K | −$274K | -33% |
| Working capital & other | $3.1M | −$3.2M | $6.2M | — |
| Cash used in operations | $1.2M | $3.5M | −$2.3M | -66% |
| Net loss absorbed | $5.1M | $1.5M | $3.6M | +247% |
Questions
How much did Cytosorbents's revenue grow year over year in Q1 2026?
Cytosorbents's revenue rose $137K (+2%) from $8.7M in Q1 2025 to $8.9M in Q1 2026.